Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.80 |
| ▸ | CCND1 | P24385 | 17/20 | 0.80 |
| ▸ | CCND3 | P30281 | 11/20 | 0.80 |
| ▸ | CCND2 | P30279 | 10/20 | 0.80 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.64 |
| ▸ | CDK2 | P24941 | 5/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.64 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.64 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.64 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.64 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.63 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.61 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.61 |
| ▸ | CDK9 | P50750 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507452 | 0.92 | CDK4 (0.87) | CDK4CCND1CCND3CCND2CCNA2 | |
| SCHEMBL4826062 | 0.92 | CDK4 (0.87) | CDK4CCND1CCND3CCND2CCNA2 | |
| SCHEMBL30176501 | 0.91 | CDK4 (0.85) | CDK4CCND1CCND3CCND2CCNA2 | |
| SCHEMBL4828621 | 0.91 | CDK4 (0.85) | CDK4CCND1CCND3CCND2CCNA2 | |
| SCHEMBL15874874 | 0.91 | CDK4 (0.77) | CDK4CCND1CCND3CCND2CCNA2 | |
| SCHEMBL15874554 | 0.89 | CDK4 (0.80) | CDK4CCND1CCND3CCND2CCNA2 | |
| SCHEMBL29507484 | 0.89 | CDK4 (0.81) | CDK4CCND1CCND3CCND2CCNA2 | |
| SCHEMBL4828461 | 0.89 | CDK4 (0.81) | CDK4CCND1CCND3CCND2CCNA2 | |
| SCHEMBL29507528 | 0.89 | CDK4 (1.00) | CDK4CCND1CCND3CCND2CCNA2 | |
| SCHEMBL15874498 | 0.89 | CDK4 (0.77) | CDK4CCND1CCND3CCND2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180087079-A1 | METHODS OF USING CELL-CYCLE INHIBITORS TO MODULATE ONE OR MORE PROPERTIES OF A CELL CULTURE | AMGEN INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20150353542-A1 | METHODS OF USING CELL-CYCLE INHIBITORS TO MODULATE ONE OR MORE PROPERTIES OF A CELL CULTURE | AMGEN INC. (US) | 2015-12-10 | — | — | US | disclosed |
| WO-2014109858-A1 | METHODS OF USING CELL-CYCLE INHIBITORS TO MODULATE ONE OR MORE PROPERTIES OF A CELL CULTURE | AMGEN INC. (US) | 2014-07-17 | — | — | WO | disclosed |
| CN-102295643-B | 2-(pyridin-2-ylamino)-pyrido[2,3d]pyrimidin-7-ones | WARNER LAMBERT CO | 2013-12-04 | — | — | CN | disclosed |
| CN-101906104-B | 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | WARNER LAMBERT CO | 2013-06-05 | — | — | CN | disclosed |
| CN-102295643-A | 2-(pyridin-2-ylamino)-pyrido[2,3d]pyrimidin-7-ones | — | 2011-12-28 | — | — | CN | disclosed |
| CN-101001857-B | 2- (pyridin-2-ylamino) -pyrido [2,3-d ] pyrimidin-7-ones | WARNER LAMBERT CO | 2011-06-22 | — | — | CN | disclosed |
| CN-101906104-A | 2-(pyridine-2-base is amino)-pyrido [2,3-d] pyrimidin-7-ones | WARNER LAMBERT CO | 2010-12-08 | — | — | CN | disclosed |
| CN-101001857-A | 2- (pyridin-2-ylamino) -pyrido [2, 3-d ] pyrimidin-7-ones | WARNER LAMBERT CO (US) | 2007-07-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180087079-A1 | METHODS OF USING CELL-CYCLE INHIBITORS TO MODULATE ONE OR MORE PROPERTIES OF A CELL CULTURE | CDKN1A, CDC25C, CDC25B | CDK4 18/4885CCND1 52/4885CCND3 58/4885 |
| US-20150353542-A1 | METHODS OF USING CELL-CYCLE INHIBITORS TO MODULATE ONE OR MORE PROPERTIES OF A CELL CULTURE | CDKN1A, CDC25C, CDC25B | CDK4 18/4885CCND1 52/4885CCND3 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.